drugset

drugset / Trial / NCT06188455

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

NCT06188455 ↗

Phase 3 Not yet recruiting 37 enrolled The First Affiliated Hospital of Xiamen University

NaSingle-groupOpen-labelTreatment

Summary

Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled

Timeline

Start: 2024-12-01
Primary completion: 2025-12-01
Completion: 2026-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fluzoparib	Small molecule	100 mg	Oral
Subject	Rivoceranib	Small molecule	250 mg	Oral

Indications